chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received on 13-APR-2018 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 18-NOV-2008, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route, at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 22-SEP-2014, the patient was treated at a medical clinic for a blistering vesicular outbreak which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
After the second vaccine, 4/2/21 The signs were in the afternoon I started coughing blood clots and then nothing else.
Patients experienced muscle pain and chills for 2 days post vaccination. Symptoms resolved without intervention.
tested positive for covid-19 after vaccination; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive for covid-19 after vaccination) and FEELING ABNORMAL (felt badly) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Sep-2021, the patient experienced COVID-19 (tested positive for covid-19 after vaccination). On an unknown date, the patient experienced FEELING ABNORMAL (felt badly). The patient was treated with MONOCLONAL ANTIBODIES, GRANULOCYTE for COVID-19, at an unspecified dose and frequency. At the time of the report, COVID-19 (tested positive for covid-19 after vaccination) outcome was unknown and FEELING ABNORMAL (felt badly) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Sep-2021, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medication were reported.; Sender's Comments: This report concerns a male patient of unknown age with no relevant medical history who experienced a serious unexpected event of COVID-19. The event occurred approximately 7 months after the second dose of mRNA-1273. The report states that patient had a mild disease and was in hospital. The patient was treated with monoclonal antibodies. Re-challenge was not applicable as the event happened after the second dose, and no additional dosing will be given. There is no information about the first dose. Outcome of the event COVID-19 was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Information has been received from a legal firm regarding a case in litigation concerning a 24 month old male child who was injected with vaccines from 4/30/95 through at least 10/15/94, reportedly containing the mercury-based preservative thimerosal. The vaccines included at least the following: On 1/30/95, 4/3/95 and 12/1/95, the first, second and third doses of hep  B vaccine, recombivant (manuf unk). On 4/3/95 diphtheria, pertussis, and tetanus, oral polio vaccine, haemophilus influenza type B; on 5/31/95 diphtheria, pertussis, and tetanus, oral polio vaccine, haemophilus influenza type B; on 8/9/95 diphtheria, pertussis, and tetanus, haemophilus influenza type B; on 2/2/96 MMR vaccine live; on 5/8/96 haemophilus influenza type B; on 10/15/97 diphtheria, pertussis, and tetanus, and oral polio vaccine. It is alleged that after the pt was exposed to thimerosal, his behavior changed dramatically by the end of his second year. He avoided eye contact with his parents, indicated a strong preference for being left alone, and would bounce. He stopped talking and playing. In or around October 1998, he was diagnosed with autism. Upon internal review, the pt's autism was considered to be an important medical event (OMIC). No other info was available.
This spontaneous report was received from a medical assistant referring to unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients may have received an unknown number of improperly stored doses of GARDASIL 9 (dose, route of administration, lot numbers and expiration dates were not reported) for prophylaxis. There were no adverse effects reported in any patients. Administered doses of GARDASIL 9 were exposed to a temperature excursion of below 32°F/0°C for 105 hours. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same source. Additional information has been requested. Sender's Comments: US-009507513-1702USA010265: US-009507513-1703USA006287.
Approximately 1 week following vaccination, patient developed new onset of right sided hemisensory loss and paresthesia with feeling of mild vertigo.  This worsened over the following 4-5 days prompting patient to come to hospital on January 3, 2021 for further evaluation.
tongue & lips swelled;ears swelled-eyes swelled, lower jaws swelled;broke out all over in huge hives;still feeling very very very weak & dizzy;60 day follow-up / no additional data.
This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown. It was unknown if the reporter considered the pain in arm to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient experienced mild sore arm after receiving 1st dose of SHINGRIX. This case is linked to case US2019056560, due to same patient.
pt recvd vax 236SEP93 & 1 month later became pregnant; 30JUN94 @ 37 wks gestation delivered a 7lb male baby; pt was placed under bililights for 1 day for treatment of jaundice; No further details were provided;
Flu like symptoms, Chills, Headache, vomitting, seizure, fainting, severe pain in the stomach and the middle of the back like being punched, cramping in muscles especially the legs. I had to be rushed to the emergency room at the nearest hospital. They did many tests as well as a full body CAT scan. The pain would not stop until I was given Morphine.
Moderna COVID-19 Vaccine EUA.  2ND injection.  Mild red rash around injection site.  Itchy.
Pt. lied about his vaccination history. Claimed he never had Covid vaccine before. Nurse found out after his vaccination that he already received 2 doses.
Child was well, became suddenly sleepy, then experienced generalized tonic-clonic seizure x1-2 minutes. In ED Temp 38.9-->39.8.  No other symptoms, and appeared well.  Diagnosed febrile seizure.  No further evaluation or sequelae.
After vaccine administration-pt cried immediately then vomited within five minutes of shot. Child ? wheezing, vomited again, not breathing well; crying whole time. Epipen Jr given. Transferred via 911 to ER. The hospital summary received on 4/6/04 states tremulous, and an allergic react to vaccine.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 63-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 05Jan2023 as dose 5 (booster), single (Lot number: GL0446) at the age of 62 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "GERD" (unspecified if ongoing); "Hypertension" (unspecified if ongoing); "Hiatal hernia" (unspecified if ongoing); "Known allergies: CT contrast dyes" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Lisinopril, reaction(s): "Known allergies: lisinopril"; Losartan, reaction(s): "Known allergies: losartan". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. Additional information: Patient received COVID 19 Treatment from 29Jan2023 to 03Feb2023.
Shortness of Breath after second vaccine; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Shortness of Breath after second vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Shortness of Breath after second vaccine). At the time of the report, DYSPNOEA (Shortness of Breath after second vaccine) outcome was unknown.            No Concomitant Medications were provided by the Reporter  No Treatment Information were provided by the Reporter   Reporter did not allow further contact
This spontaneous report as received from a health professional refers to a 85 year old female patient. On 14-JUL-2017, the patient was vaccinated with a dose of PNEUMOVAX 23 lot # M047519, lot # N011491 or lot# N001007 for immunisation. On 14-JUL-2017, the patient experienced erythema, musculoskeletal pain, peripheral swelling and pain in extremity. The outcome of erythema, peripheral swelling, musculoskeletal pain and pain in extremity was reported as recovered. This is one of several reports from the same reporter who mentioned that multiple lot numbers resulted in a adverse event, but was unsure which patient received which vaccine. Sender's Comments: US-009507513-1707USA008579: US-009507513-1707USA008989: US-009507513-1707USA007889.
felt the injection needle pinch his arm.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (felt the injection needle pinch his arm.) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE PAIN (felt the injection needle pinch his arm.). At the time of the report, VACCINATION SITE PAIN (felt the injection needle pinch his arm.) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No concomitant medication was provided.  The patient received the vaccine in his left arm shoulder deltoid muscle.  No treatment medication was provided.   This case was linked to MOD-2022-509786, MOD-2022-509820.
Report HA,  left arm swelling, and fever 100.8. Treatment: None. Outcome: Did not got into work, will monitor symptoms and take OTC Tylenol or Ibuprofen. Does not interfere with ADLs.
Evening symptoms, injection site pain, mild headache, sleeplessness caused by mild limb spasms till 1:00 am. Spasm symptoms seem to have subsided, headache remained mild. able to fall asleep. Awoke at 5:30 (normal time) seemed good other than arm soreness. By 8 am I developed Vertigo like symptoms. 48hrs after injection this morning, the headache is gone but vertigo symptoms remain however lesser than the previous day.
Initial (starting next day) - I began feeling achy, which went away after about one day. For several days I was more tired than usual and "passing out" at night earlier than I normally go to bed.  Concerning event - beginning the evening of 19 FEB 21, I began feeling tired and achy and a fever set in. From 20-27 FEB I regularly had a fever of 102-104 degrees Fahrenheit. I went to the hospital on 21 FEB after over 24 hours with a fever and a heart rate of about 115 bpm with concern of afib. During this period (20-27 FEB) I believe my heart rate did not drop below 90 bpm and was regularly in the range of 110-115 bpm. While sleeping my heart rate was commonly in the high 90s. I did not experience afib. I lost approximately 15 lbs during that week and was unable to eat. Since then I have not been able to eat a full meal based on my eating habits prior to being vaccinated. I have continued to lose weight slowly (1-2 lbs per week), but my weight will fluctuate back up by 1-2 lbs as my bowel movements are infrequent. I am currently only eating about once per day with limited snacking. I use Ensure and my vitamins to avoid concerns of malnutrition.
Patient had their first Moderna primary dose on 18Mar2022, and would to know what to do for the second dose; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Patient had their first Moderna primary dose on 18Mar2022, and would to know what to do for the second dose) and NO ADVERSE EVENT (No adverse event) in a female patient of an unknown age who received mRNA-1273 (Spikevax) (batch no. 026L21B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Mar-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Patient had their first Moderna primary dose on 18Mar2022, and would to know what to do for the second dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Patient had their first Moderna primary dose on 18Mar2022, and would to know what to do for the second dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (Patient had their first Moderna primary dose on 18Mar2022, and would to know what to do for the second dose).    No concomitant medications were reported.  No treatment information was provided.
chills and severe aches 20 hours post shot that lasted for about 12 hours and seemed to clear up; 5 days later developed low grade temp, chills, and severe joint aches - specifically in hips and thighs.
The patient presented to the Medical Center on 02/17/2022 with SOB.  She was diagnosed with Covid-19 1 month prior.  Over the past two weeks, the patient has had worsening body aches, fevers, generalized weakness, SOB, cough, HA, and nausea.  She was given multiple courses of antibiotics and steroids by her PCP.  On arrival at the ED, the patient's oxygen was 89% on RA.  CT Regulatory AUthority study showed moderate bilateral PNA, left worse than right.  The patient was given IV fluids and antibiotics in the ED.  The patient was admitted to the hospital.  During her hospitalization, oxygen requirements continued to trend up.  The patient was transferred to the ICU on 03/04/2022 for worsening hypoxemia.  The patient decided on DNR.  The patient remained on vapotherm and nonrebreather.  The patient transitioned to comfort care.  The patient expired on 03/06/2022.
Shortly after my shot swollen tongue, difficulty swallowing, hard to catch my breathe, took Benedryl at the recommendation of the pharmacy. Symptoms didnt worsen so I stayed home. Next morning I noticed my eyes were swollen(they might have been swollen the day before but I didnt notice until the next morning ), red splotchy skin, extreme fatigue, shortness of breathe, fever, cough, difficulty lifting my right arm(where I got the injection). Injection site is still red and painful to touch and with certain muscle movements. Today Wednesday(shot was on Monday) I still have a fever of 99.9(with Tylenol), shortness of breathe, occasional cough, lack of appetite, dizziness when standing, headaches(with Tylenol), arms are no longer splotchy but still minor splotchy redness on my trunk(stomach and chest)and fatigue fluctuates between extreme to medium.
after about 10 minutes patient went weak and muscles went into tetani for a brief time .911 was called .Patient recovered well in a sitting position bu then some minutes later p[resented with syncopy. He was placed on floor with legs raised and did recover some time later. The para medics put up a drip and took him away . Patient does not return my calls to find out status
Patient pulled arm away when administering vaccine. Had to re-stick patient to administer vaccine. Whole dose administered with 2nd needle stick to arm.
The below started on 5/7/2021 in the late evening while sleeping.   Body aches and chills for ~2 days controlled with Motrin and Tylenol. Swelling in face and dizziness for ~2-3 days Dizziness/light headed ongoing depending on movement.
Patient's injection site was red and itchy, gave 1.5 tablets of diphenhydramine 25mg, patient was monitored for an extra 15 minutes and felt fine so went home
The patient fainted shortly after the vaccine was given. He was in a seated position at the time, and regained consciousness within a few seconds. He described feeling sweaty, weak, and dizzy upon regaining consciousness. He had a snack, water, and remained seated for about 30 minutes after vaccination. He began feeling better within a few minutes of regaining consciousness.
Expired Havrix administered; This non-serious case was reported by a physician via call center representative and described the occurrence of expired vaccine used in a 2-year-old male patient who received HAV (Havrix) (batch number T57F3, expiry date 16-FEB-2023) for prophylaxis.   On 03-APR-2023, the patient received Havrix. On 03-APR-2023, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: Expired Havrix administered). The outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 05-APR-2023  The physician reported an expired dose of Havrix was administered to a patient. The reporter consented to follow up via phone. The patient received an expired dose of Havrix, which led to expired vaccine used.
37yo Female, presenting with bilateral foot pain/burning sensation since receiving 2nd COVID moderna vaccination on 4/4. Symptoms also included fever, HA, fatigue, which resolved with exception of still feeling fatigue and foot pain. With the foot pain, has not improved, spends most of day on feet, worse pain at end of day. She also noted about 6 small new bruises from knees down, but was unable to show on video (patient at work), but no bruises on feet. Normal appearing feet, patient feels more swollen. Last CBC 1/2020, normal platelets. Denies CP, SOB, leg swelling, erythema. concern whether neuropathy  is a side effect of vaccination.
Grew a swollen lymph node in groin; This case was reported by a consumer and described the occurrence of lymphadenopathy inguinal in a 62-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced lymphadenopathy inguinal. On an unknown date, the outcome of the lymphadenopathy inguinal was unknown.   It was unknown if the reporter considered the lymphadenopathy inguinal to be related to Shingrix.  Additional information received were as follows: The age at vaccination was not reported. The patient experienced a swollen lymph node in groin. The patient asked did the vaccine cause that the patient never had before. The patient asked whether if the patient was alone or whether they had other complaints. The pharmacist replied that one patient reported lymphadenitis and 1 subject and another patient reported fever greater than 39 degree C. There was a basis for a causal relationship with Shingrix. The patient's doctor thought that the event was caused from the shot. The node popped up in 2 days. The patient told if was in 4 weeks still there then a biopsy was scheduled.
Extreme fatigue, muscle aches like with having a flu, runny nose, small cough.
Complained of some itching at right upper arm injection site.  No evidence of swelling, rash or redness at site. Released after assessed by MD.
Chills when went to bed on 21st, of Dec, 2020. Woke around 2 am on 22nd of Dec with joint pain in my hips and hot.  I hurt everywhere in my body when I got up, Felt hot, sweaty and weak. Temp 101.6.  Took tylenol 1000mg, for fever and drank lots of water to flush my system. Headache  all day. Felt bad rest of day, with low grade fever 99. Taking excederin or tylenol q 4-6 hours alternating.   Slept better night of 22-23; woke  with headache and just feeling wiped out.  No joint pain today. no elevated temp. the  site of the injection was sore, hot and swollen.  Felt better on Thurs. 24.
My right arm is not useable any more.  Immediate pain when I put weight on it or go to lift anything.
nasal congestion/ nose is stopped up; Fever; body ache; Headache; Muscle soreness; Chills; tired; This is a spontaneous report from a  contactable consumer reporting for herself.   A 59-years-old female patient  received the second dose of bnt162b2 (BNT162B2; Lot # EL0142) , via an unspecified route of administration on  08Jan2021 11:00 at single dose  for Covid-19 immunisation .  The patient medical history and concomitant medications were not reported. The first dose of the vaccine was given on an unknown date. The patient experienced chills  on 08Jan2021 23:00 with outcome of recovering , fever  on 09Jan2021 with outcome of recovered , body ache  on 09Jan2021 with outcome of recovering , headache  on 09Jan2021 with outcome of recovered , muscle soreness on 09Jan2021 with outcome of recovering , tired  on 08Jan2021 with outcome of recovering , nasal congestion/ nose is stopped up  on an unspecified date with outcome of recovered.  Paracetamol (TYLENOL) was taken as a result of chills.